Precision Medicine

Pushpanathan Muthuirulan

13 August 2018 | By

Research Associate, Harvard University

Scientists counter epigenetic reprogramming for ischemic cardiomyopathy patients

10 August 2018 | By Drug Target Review

Congestive heart failure is a terminal disease that affects nearly 6 million people in the U.S.; yet its management is limited to symptomatic treatments as its causal mechanisms – including its most common form, ischemic cardiomyopathy – are unknown.

Transforming translational research: CANscript^TM – a better predictive model for oncology

8 June 2018 | By Mark Paris

This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.

13th International Conference on Metabolomics and Systems Biology

18 May 2018 | By Conference Series LLC

Euro Metabolomics 2018 will be a platform to investigate on recent research and advancements that can be useful to the researchers.

Cellular reprogramming promotes muscle regeneration in injured mice

9 May 2018 | By Drug Target Review

Scientists have developed a simple and robust approach for directly reprogramming mature skin cells into immature muscle cells...

Study provides insight into blood signatures of inflammation

9 May 2018 | By Drug Target Review

A new study has identified a pattern of inflammation associated with cardio-metabolic risks...

ALS researchers begin recreating human spinal cords on a chip

30 April 2018 | By Dr Zara Kassam (Drug Target Review)

NIH-funded study closes in on personalised drug testing for neurological disorders...

Transforming translational research: CANscript^TM – A better predictive model for oncology

27 April 2018 | By Mitra Biotech

In this webinar, speaker Mark Paris, PhD discussed a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript TM;. He also be reviewed the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.

Biomarker endpoints for Parkinson’s disease

26 April 2018 | By Charles River Laboratories

This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.

Rare brain disease in children: Major breakthroughs in Rasmussen’s encephalitis

11 April 2018 | By Dr Zara Kassam (Drug Target Review)

Chronic focal encephalitis is a rare and devastating inflammatory brain disease, researchers have proven that the disease attacks patients using their own immune system...

How the study of lipidomics is benefiting from recent advances in mass spectrometry

10 April 2018 | By Cristina Legido-Quigley (Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen)

There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.

An advance for precision medicine

10 April 2018 | By Drug Target Review

Discovery allows scientists to index thousands of cells simultaneously, a 40-fold increase from the current method...

Mitra Biotech

3-D tissue model of developing heart could help drug safety testing

20 March 2018 | By Drug Target Review

Researchers have combined biomaterials-based cell patterning and stem cell technology to make a 3D tissue model that could mimic early stage human heart development...

Under the microscope: Choosing the best microplate reader

19 March 2018 | By Mark Wigglesworth (Director High-Throughput Screening - AstraZeneca)

Efficient microplate readers play an important role in effective hit molecule discovery. Mark Wigglesworth, of AstraZeneca, explains what he looks for in this technology.